These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36929498)

  • 21. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis.
    Chen F; Wang D; Shu X; Nakashima R; Wang G
    Rheumatol Int; 2012 Dec; 32(12):3909-15. PubMed ID: 22198664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease.
    Gao Y; Zhao Q; Xie M; Yan X; Li Y; Zhang X; Wu H; Dai J; Cao M; Cai H
    Cytokine; 2020 Nov; 135():155209. PubMed ID: 32738770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis.
    Gui X; Ma M; Ding J; Shi S; Xin X; Qiu X; Zhang Y; Qiu Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
    Rheumatology (Oxford); 2021 Aug; 60(8):3913-3922. PubMed ID: 33501503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
    Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
    Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report.
    Yen TH; Tseng CW; Wang KL; Fu PK
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics of and risk factors for Pneumocystis jirovecii pneumonia in anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody-positive dermatomyositis patients: a single-center retrospective study.
    Li J; Wang S; Zheng J; Li Q; Li J; Lu L
    Clin Rheumatol; 2023 Feb; 42(2):453-462. PubMed ID: 36301369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
    Matsuda KM; Yoshizaki A; Kuzumi A; Fukasawa T; Ebata S; Yoshizaki-Ogawa A; Sato S
    J Dermatol; 2020 May; 47(5):483-489. PubMed ID: 32096271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.
    McPherson M; Economidou S; Liampas A; Zis P; Parperis K
    Semin Arthritis Rheum; 2022 Apr; 53():151959. PubMed ID: 35134633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
    Sonomoto K; Yamaoka K; Kubo S; Hirata S; Fukuyo S; Maeshima K; Suzuki K; Saito K; Tanaka Y
    Rheumatology (Oxford); 2014 May; 53(5):914-8. PubMed ID: 24441153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of mortality for dermatomyositis patients positive with anti-melanoma differentiation-related gene 5 and optimal treatment.
    Liu L; Zhang Y; Shu X; Wang C; Guan W; Zhang X; Zhang L; Liu X; Wang L; Liu S; Li T
    Clin Exp Rheumatol; 2024 Feb; 42(2):246-252. PubMed ID: 37199165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
    Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
    Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis.
    Takatani A; Koga T; Fujita Y; Fukui S; Endo Y; Shimizu T; Kawakami A
    Clin Immunol; 2020 Jun; 215():108451. PubMed ID: 32360518
    [No Abstract]   [Full Text] [Related]  

  • 33. Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients.
    Qian J; Li R; Chen Z; Cao Z; Lu L; Fu Q
    Front Immunol; 2023; 14():1151695. PubMed ID: 37006269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
    Weinhold KJ; Bukowski JF; Brennan TV; Noveck RJ; Staats JS; Lin L; Stempora L; Hammond C; Wouters A; Mojcik CF; Cheng J; Collinge M; Jesson MI; Hazra A; Biswas P; Lan S; Clark JD; Hodge JA
    Clin Immunol; 2018 Jun; 191():10-20. PubMed ID: 29518577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis.
    Tsuji H; Nakashima R; Hosono Y; Imura Y; Yagita M; Yoshifuji H; Hirata S; Nojima T; Sugiyama E; Hatta K; Taguchi Y; Katayama M; Tanizawa K; Handa T; Uozumi R; Akizuki S; Murakami K; Hashimoto M; Tanaka M; Ohmura K; Mimori T
    Arthritis Rheumatol; 2020 Mar; 72(3):488-498. PubMed ID: 31524333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis.
    Gono T; Sato S; Kawaguchi Y; Kuwana M; Hanaoka M; Katsumata Y; Takagi K; Baba S; Okamoto Y; Ota Y; Yamanaka H
    Rheumatology (Oxford); 2012 Sep; 51(9):1563-70. PubMed ID: 22589330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients.
    Xue Y; Zhang J; Deng J; Kuang W; Wang J; Tan X; Li C; Li S; Li C
    Ann Rheum Dis; 2023 Nov; 82(11):1499-1501. PubMed ID: 37280048
    [No Abstract]   [Full Text] [Related]  

  • 38. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
    Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
    Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis.
    Jin Q; Fu L; Yang H; Chen X; Lin S; Huang Z; Gao B; Tian X; Jiang W; Shu X; Lu X; Wang G; Peng Q
    J Intern Med; 2023 Apr; 293(4):494-507. PubMed ID: 36682032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated serum B-cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease.
    Matsushita T; Kobayashi T; Kano M; Hamaguchi Y; Takehara K
    J Dermatol; 2019 Dec; 46(12):1190-1196. PubMed ID: 31631384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.